Orelabrutinib With R-CHOP-like Regimen for Patients With Newly Diagnosed Untreated Non-GCB DLBCL
Status:
Recruiting
Trial end date:
2025-01-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy and safety of orelabrutinib combined
with rituximab，followed by orelabrutinib combined with R-CHOP-like regimen for newly
diagnosed untreated Non-GCB DLBCL Patients
Phase:
Phase 2
Details
Lead Sponsor:
The First Affiliated Hospital of Soochow University